Proactive Investors - Run By Investors For Investors

Nanobiotix boss upbeat as cancer technology passes latest test

Laurent Levy, Nanobiotix’s (EPA:NANO) chief executive, expects newsflow will continue strongly following the good results of a combined safety and dosing trial of its lead product in head and neck cancer patients.
The treatment, which boosts the effectiveness of radiotherapy by combining it with nanotechnology, was well-tolerated with no signs of leakage said Levy, with evidence as well of tumour shrinkage in most patients.
A number of clinical trial options in the head and neck cancer arena are now being assessed both in Europe and the US, Levy said.
In addition more results from application of its nanotechnology in soft tissue sarcoma and liver cancer are due later this year.

Meet Yellow Cake PLC, Avation PLC, Manolete Partners PLC and Crossword Cybersecurity Plc at our event, London , 05 September 2019. Register here »
View full NANO profile View Profile

Nanobiotix SA Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use